Telomir Pharmaceuticals, Inc. Common Stock

NASDAQ:TELO

Biotechnology

Healthcare
$0.69 -3.42%

-$0.04 today

Market cap
$50.84M
Beta
-0.24
P/E (TTM)
-3.8
EPS (TTM)
-$0.27
52W Low $0.89High $2.09

Volume 0.17M

Average 0.13M

TELO Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 34.38M shares rose 15.5% year over year, ahead of the +9.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +2.2% a year.

Context

  • Weighted avg shares increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +15.5% holds above the trailing-twelve-month pace of +9.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
34.38M+0.0% QoQ
Last fiscal yearDec 2025
31.65M+7.2% YoY
LTMMar 2026
32.45M+9.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.5%——
1 year+7.2%——
3-year CAGR+2.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
31.65M USD
Year-over-year change
+7.2%
4-year CAGR
+1.7%

Weighted Avg Shares vs competitors

How TELO compares with its peers on the latest reported figures

  • TELO's LTM Mar 2026 weighted avg shares of 32.45M shares is the 3rd highest of the 6 companies compared; the peer median is 25.76M shares.
  • Its year-over-year change of +9.5% is the 4th highest of 6, against a peer median of +22.3%.
  • Over three fiscal years its annual growth of +2.2% compares with a peer median of +14.4%.
TELO Competitors Peer median
Weighted Avg Shares for TELO and competitors
Company Period LTM YoY 3-year CAGR
IPSCCentury Therapeutics, Inc.LTM Mar 202686.45M +4.3%+14.4%
EQEquillium, Inc.LTM Mar 202664.9M +83.3%+39.7%
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 202632.45M +9.5%+2.2%
INMBINmune Bio, Inc.LTM Mar 202625.76M +22.3%+14.0%
KPTIKaryopharm Therapeutics Inc.LTM Mar 202614.32M +72.2%+26.1%
COEPCoeptis Therapeutics, Inc.LTM Mar 20264.68M -77.3%-33.3%
Peer median (excluding TELO) 25.76M+22.3%+14.4%

Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development126.49K833.21K1.57M2.24M2.44M
Selling, General & Admin11.64K20.94K600.19K9.64M8.1M
Operating Expenses138.13K854.15K3.94M12.24M10.54M
Depreciation & Amortization138.13K854.15K012.24M0
EBITDA00(11.43M)48K(10.41M)
EBITDA Margin—————
Operating Income(138.13K)(854.15K)(3.94M)(12.24M)(10.54M)
Operating Margin—————
Interest Income00048K125.64K
Interest Expense001.64M(4.34M)0
Other Income / Expenses00(9.13M)(4.29M)125.64K
Income Before Tax(138.13K)(854.15K)(13.07M)(16.53M)(10.41M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(138.13K)(854.15K)(13.07M)(16.53M)(10.41M)
Net Margin—————
EPS (Basic)(0.00)(0.03)(0.44)(0.56)(0.33)
EPS (Diluted)(0.00)(0.03)(0.44)(0.56)(0.33)
Weighted Avg Shares29.61M29.61M29.61M29.54M31.65M
Weighted Avg Shares (Diluted)29.61M29.61M29.61M29.54M31.65M

Telomir Pharmaceuticals, Inc. Common Stock

NASDAQ:TELO

Intrinsic Alpha fair value

Locked

Current Price

$0.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.